Ann Arbor, MI-Urologists should use biopsy, not barbotage cytology, to assess tumors and select treatment for upper-tract urothelial carcinomas, advise researchers at the University of Michigan Urology Center in Ann Arbor.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.